January 16, 2024 2 min read

The BiliDx is a novel system for diagnosing jaundice.  The device uniquely meets the Target Product Profile (TPP) developed as part of the NEST 360 initiative in that it allows blood-based testing at the bedside.   This initiative is part of an emerging global consensus in the Every Newborn Action Plan that countries need functional WHO level-2 inpatient units to care for "small and sick newborns." 

Why is diagnosis of jaundice so critical?

Though often referred to as 'yellow skin', jaundice may become severe without visible clinical symptoms.  Often infants are sent home, only to develop more severe jaundice at home.  Not only is a blood-based bilirubin test needed for initial diagnosis, but for ongoing monitoring of the effectiveness of phototherapy (blue light).  

The problem in low-resource settings

In many hospitals and clinics, there is simply no reliable way to test infants for jaundice.  In places where a laboratory is available, the turnaround time can be hours.  The TPP for a bilirubinometer stated, "The ideal solution in a low-resource setting would be a reliable point-of-care test which can test serum bilirubin both before and during phototherapy treatment." If not treated, severe jaundice can eventually lead to irreversible neurological damage.

Why the BiliDx is Novel

At Maternova we research and then distribute innovative medical devices that have a strong clinical profile behind them.  The BiliDx data from Malawi has been published in The Lancet and other peer-reviewed journals.  The data showed that the BiliDx allowed a level of precision that is higher than the transcutaneous bilirubinometers (these rely upon light shining through the skin of the newborn). 

The BiliDx system of a reader and lateral flow cassettes meets the Target Product Profile set forth by NEST 360.  Now clinicians have the ability to immediately identify newborns with jaundice and then monitor treatment with phototherapy with a high level of accuracy.  

The BiliDx provide lab-quality results from a whole blood heel stick in 10 minutes at the point of care.  The device operates on a rechargeable, battery operated (standard USB charger 110 – 220V AC), lasting up to 24 hours.  600 tests can be run on a battery charge.

 

Leave a comment

Comments will be approved before showing up.


Also in The Maternova Blog

The bubble CPAP reducing neonatal mortality by 27 percent
The bubble CPAP reducing neonatal mortality by 27 percent

September 04, 2024 2 min read

NIgerian experience with a pilot in 7 hospitals using the bubble CPAP.
Read More
DreamWarming, infant warming mattress, infant transport mattress, infant hypothermia solution
An innovation in the warm chain: The DreamWarmer

June 24, 2024 2 min read

The warming mattress (made up of strips of phase change material) can stay warm for 6 or more hours.  It is a flexible mattress that can be used in conjunction with skin to skin contact or with Kangaroo Mother Care.
Read More
antenatal corticosteroids expert advice from FIGO
Antenatal corticosteroids: FIGO states they should not be given “just in case”

June 06, 2024 2 min read

According to the American College of Obstetricians and Gynecologists (ACOG) and the International Federation of Gynecology and Obstetrics (FIGO), the administration of antenatal corticosteroids is recommended in women with a pregnancy between 24 and 34 weeks who are at risk of preterm birth within the next seven days.
Read More